America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy’.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
How does AOH1996 specifically target cancer cells, and what role does the protein PCNA play in its mechanism of action?
**Interview with Dr. Linda Malkas on the Development of Targeted Chemotherapy Drug AOH1996**
**Interviewer:** Thank you for joining us today, Dr. Malkas. You’ve been at the forefront of developing AOH1996, a promising new drug for treating various cancers. Could you start by explaining how this drug works?
**Dr. Malkas:** Thank you for having me. AOH1996 is a groundbreaking molecule that targets a variant of the protein PCNA, which plays a crucial role in DNA replication and tumor growth. Think of PCNA as a major airport hub; AOH1996 acts like a blizzard that disrupts operations, specifically targeting the ‘flights’ that deliver cancer cells, effectively inhibiting their growth and survival.
**Interviewer:** That’s a fascinating analogy! Can you tell us about the types of cancers that AOH1996 has shown effectiveness against?
**Dr. Malkas:** Absolutely. In our clinical research, AOH1996 has demonstrated effectiveness in treating various cancers, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. Over the past two decades, we have conducted extensive studies, including testing this drug on over 70 cancer cell lines, which showed promising results in selectively killing cancer cells.
**Interviewer:** The development of AOH1996 seems to have been a lengthy process. What were some of the key stages in its development?
**Dr. Malkas:** Yes, it has taken many years of research. We focused on understanding the unique mutations present in the cancer variant of PCNA, which allowed us to design a targeted approach. Our studies culminated in the findings published in the journal *Cell Chemical Biology*, where we showcased how AOH1996 disrupts the normal reproductive cycle of cancer cells, leading to their destruction.
**Interviewer:** That sounds very promising! What are the next steps for AOH1996?
**Dr. Malkas:** The next critical phase involves advancing our findings through human clinical trials. We are currently preparing for this step, as it’s crucial to validate the safety and efficacy of AOH1996 in actual patients. Our team at City of Hope is committed to this mission, aiming to bring this novel treatment option to those who need it most.
**Interviewer:** It’s inspiring to hear about the commitment to advancing cancer treatment. Is there any message you’d like to share with those affected by cancer?
**Dr. Malkas:** I want to reassure patients and their families that research is continually evolving, and new treatments like AOH1996 are on the horizon. We are dedicated to finding more effective and targeted therapies to improve outcomes and quality of life for cancer patients. Stay hopeful and informed; you are not alone in this journey.
**Interviewer:** Thank you so much for your insights, Dr. Malkas. We look forward to hearing more about AOH1996 and its future in cancer therapy.
**Dr. Malkas:** Thank you! It’s been my pleasure to share our progress.
